Background: Diabetes summer camp is a demanding, although joyful, setting with many unpredictable activities affecting glycemic control. Recent technological advances, such as automated insulin delivery (AID) systems, offer promising real-world benefits. Our aim was to evaluate the efficacy and safety of continuous subcutaneous insulin infusion (CSII) systems during a diabetes summer camp and compare the performance of the MiniMed 780G (AID) system with the sensor-augmented MiniMed 640G system. Methods: This is a retrospective, observational study collecting data from six summer camp weeks organized from 2019 to 2025 in Northern Greece. Children, adolescents, and adult staff with type 1 diabetes (T1D) using MiniMed insulin pumps and continuous glucose monitoring were included. Glycemic metrics (time in range, glucose coefficient of variation, time in hypoglycemia/hyperglycemia, glycemia risk index) were collected from CareLink platform across three weekly periods: during camp, pre-camp, and post-camp. Results: Data from 93 participants/year (67 females,72.04%) were included. Mean time in range (TIR) during camp was 72.72%, with best outcomes in years 2023 to 2025 (TIR > 77%). Across all periods, MiniMed 780G users demonstrated markedly superior outcomes compared to 640G users: during the camp week, TIR was 78.68% vs 62.83% ( P 180 mg/dL (22.67% vs 30.71%, P < .001). Camp weeks were associated with improved TIR and reduced hyperglycemia overall without increased hypoglycemia rates. Conclusion: Diabetes camps promote satisfactory glycemic control in youth with T1D, particularly when using AID systems. MiniMed 780G users maintained better outcomes even the week after camp compared to MiniMed 640G users.
Sotiriou et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: